Day: May 20, 2022

RIO DE JANEIRO, Brazil, May 20, 2022 (GLOBE NEWSWIRE) — Vinci Partners Investments Ltd. (NASDAQ: VINP) (“Vinci Partners”, “we”, “the Company”, “us” or “our”), the controlling company of a leading alternative investment platform in Brazil, aligned with its continuous efforts towards governance’s best practices, announced today the release of its annual Environmental, Social & Governance (“ESG”) report. This is the first ESG Report written by Vinci Partners, referring to the year 2021. The document was prepared based on Global Reporting Initiative (GRI) standards, in the Essential option, and follows the best practices of transparency, management and information disclosure to the market. “Among the important actions on this issue, I highlight the establishment of the ‘ESG Forum – Vinci’s Invested Companies’ to bring...

LEXINGTON, Mass., May 20, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213 (the ‘213 Patent), “NMR Methods and Systems for the Rapid Detection of Tick-Borne Pathogens”. The ‘213 Patent covers the T2Lyme™ Panel, which identifies the bacteria that cause Lyme disease directly from a patient’s blood in 3 to 5 hours. The T2Lyme Panel runs on the T2Dx Instrument®, the same instrument currently used to run the FDA-cleared T2Bacteria® and T2Candida® Panels. Lyme disease is a debilitating disease caused by the bacteria Borrelia burgdorferi and is transmitted to humans through the bite of infected ticks. Typical symptoms include fever, headache, fatigue...

CARLSBAD, Calif., May 20, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics Management will present a corporate overview during the H.C. Wainwright Global Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL and virtually. The presentation will provide an overview of the company’s oncology drug pipeline and recent developments in its diagnostics business. Presentation Webcast Details:Webcast Link: www.qualigeninc.com/hcw22 Viewable starting 7:00 AM ET, Tuesday, May 24, 2022 Viewable for 90 days following conferenceManagement...

Wyoming, USA, May 20, 2022 (GLOBE NEWSWIRE) — Protect Pharmaceutical Corporation, Inc. “OTC:(PRTT)” announces that after many months of strategic planning and development, the two companies are ready to announce the details of their upcoming merger. Protect Pharmaceutical Corporation, Inc. will enter into a share exchange agreement with Aetsoft (a leading blockchain solutions provider in EU region www.aetsoft.net) in order to secure its strategic goals for the web 3.0 market. The agreement is to acquire 100% of the outstanding shares of Aetsoft. Aetsoft has an extremely strong development and management team that will bring instant significant value to PRTT. The deal will drive PRTT’s position as an emerging tech innovation company and allow the consolidation of financial flows required to develop and launch the its premier products...

Iconic Burger Chain Grows Casino Locations with First Location on Las Vegas Strip LOS ANGELES, May 20, 2022 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc., parent company of Fatburger, is pleased to announce that Fatburger has officially opened in the Excalibur Hotel & Casino. The location marks the third casino location to date in Las Vegas, joining Red Rock Casino and Santa Fe Station. Hollywood’s favorite burger will also be arriving at The Venetian® Resort Las Vegas this summer. “We have seen great success with Fatburger locations in casinos over the years and are thrilled to expand upon that by opening at two iconic properties right on the Las Vegas Strip,” said Jake Berchtold, COO of FAT Brands’ Fast Casual Division. “Whether you are looking for a quick dinner before catching a show or a late-night burger...

HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review. The final condition for MedMira is to complete an additional Canadian based clinical study to supplement its existing data. At this stage, MedMira has engaged a renowned third-party in Canada and already forwarded the clinical protocol to the Ethics Committee for acceptance. At the time of receiving the acknowledgment by the...

Series  RIKB 23 0515 RIKB 42 0217Settlement Date  05/25/2022 05/25/2022Total Amount Allocated (MM)  14,343 5,700All Bids Awarded At (Price / Simple interest)  96.090 / 5.750 90.443 / 5.290Total Number of Bids Received  33 12Total Amount of All Bids Received (MM)  16,543 6,850Total Number of Successful Bids  29 9Number of Bids Allocated in Full  29 9Lowest Price / Highest Simple Interest Allocated  96.090 / 5.750 90.443 / 5.290Highest Price / Lowest Simple Interest Allocated  96.210 / 5.610 90.600 / 5.280Lowest Price / Highest Simple Interest Allocated in Full  96.090 / 5.750 90.443 / 5.290Weighted Average of Successful Bids (Price/Simple Interest)  96.146 / 5.680 90.466 / 5.290Best Bid (Price / Simple Interest)  96.210 / 5.610 90.600 / 5.280Worst Bid (Price / Simple Interest)  95.990 / 5.860 90.218 / 5.310Weighted...